Same medicine. Same results.
Lower cost.
  • Biosimilars

    Biosimilars

    GPhA applauds Congress for establishing an abbreviated...
  • Drug Shortages

    As members of the public who also are affected by...
  • Quality

    Science and quality are the cornerstones of the generic...
  • Patent Settlements

    Patent Settlements

    GPhA vigorously opposes restricting the right of parties in...
  • GDUFA

    GPhA and its member companies support full implementation...
 

Improving Lives for Less

*New data* The 2014 Generic Drug Savings in the U.S. report shows that generic pharmaceuticals saved the U.S. health system and patients $239 billion in 2013. That’s $1.46 trillion dollars in the most recent decade. This year's report discusses annual savings, 10-year savings and a breakdown by therapy area. All data were compiled by IMS Health on behalf of GPhA.   learn more >

Value and Quality

Hatch-Waxman Turns 30!

Thirty years ago, Congress created the Hatch-Waxman Act. This law is an exquisite balance between access and innovation and serves as the framework for the generic drug industry. Generic drugs today deliver public health and economic benefits far greater than anyone ever imagined. Millions of Americans rely on the access, savings and innovation made possible by this landmark law. learn more >